Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Double Blind Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.
Conditions
Interventions
Angiotensin-(1-7)
Placebo for Angiotensin-(1-7)
Locations
5
United States
Banner- University Medical Center Phoenix
Phoenix, Arizona, United States
University of Arizona Sarver Heart Center
Tucson, Arizona, United States
Suburban Hospital
Bethesda, Maryland, United States
National Institutes of Health
Bethesda, Maryland, United States
INOVA Heart & Vascular Research
Falls Church, Virginia, United States
Start Date
July 20, 2017
Primary Completion Date
November 15, 2022
Completion Date
November 15, 2022
Last Updated
June 4, 2025
NCT06223672
NCT07101380
NCT06121544
NCT07504276
NCT06395558
NCT06467539
Lead Sponsor
University of Arizona
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions